The influence of prenatal dexamethasone treatment on urinary excretion of adrenocortical steroids in newborns |
| |
Authors: | E M Małunowicz M Ginalska-Malinowska T E Romer Karol Bal |
| |
Institution: | (1) Department of Laboratory Diagnostics, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-736 Warsaw, Poland, Tel.: +48 (22) 8 15 17 07, Fax: +48 (22) 8 15 24 56, PL;(2) Department of Endocrinology, The Children's Memorial Health Institute, Warsaw, Poland, PL;(3) Department of Antidoping Research, Institute of Sport, Warsaw, Poland, PL |
| |
Abstract: | Congenital adrenal hyperplasia due to 21-hydroxylase deficiency suspected in 14 newborns (5 F, 9 M), was treated prenatally
with dexamethasone from weeks 7–9 of gestation. The 24 h urinary excretion of selected adrenocortical steroids derived from
fetal and definitive adrenal zones was evaluated in these newborns at the age of 3–9 days. Among 11 babies born healthy, in
one of six treated until confirmation of male karyotype in gestational weeks 12–17 and in four of five treated until delivery,
suppression of fetal adrenal zone steroids was observed, accompanied additionally in three by a diminished excretion of tetrahydrocortisone.
In three babies born affected (2 male, 1 female), excretion of 17α-hydroxyprogesterone and 21-deoxycortisol metabolites did
not differ from 12 affected, age-matched controls, not treated prenatally. However, some influence on suppression of the fetal
adrenal zone metabolite 16α-hydroxypregnenolone was observed in two newborns treated until delivery.
Conclusions Heterogeneity in the fetal adrenal response to maternal dexamethasone treatment was confirmed. Suppression of fetal adrenals,
especially within the fetal adrenal zone, can be observed in some babies born healthy until at least 1 week after birth.
Received: 19 August 1997 / Accepted in revised form: 9 January 1998 |
| |
Keywords: | Congenital adrenal hyperplasia Prenatal treatment Newborns Urinary adrenocortical steroids |
本文献已被 SpringerLink 等数据库收录! |
|